Cargando…
CAR-T cell therapy for hematological malignancies: History, status and promise
For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis. In recent years, immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-c...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658259/ https://www.ncbi.nlm.nih.gov/pubmed/38027932 http://dx.doi.org/10.1016/j.heliyon.2023.e21776 |
_version_ | 1785137380119805952 |
---|---|
author | Wang, Chao Wang, Jianpeng Che, Shusheng Zhao, Hai |
author_facet | Wang, Chao Wang, Jianpeng Che, Shusheng Zhao, Hai |
author_sort | Wang, Chao |
collection | PubMed |
description | For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis. In recent years, immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-cell immunotherapy (CAR-T) uses the patient's own T cells to express chimeric antigen receptors. Chimeric antigen receptor (CAR) recognizes tumor-associated antigens and kills tumor cells. CAR-T has achieved good results in the treatment of hematological tumors. In 2017, the FDA approved the first CAR-T for the treatment of B-cell acute lymphoblastic leukemia (ALL). In October of the same year, the FDA approved CAR-T to treat B-cell lymphoma. In order to improve and enhance the therapeutic effect, CAR-T has become a research focus in recent years. The structure of CAR, the targets of CAR-T treatment, adverse reactions and improvement measures during the treatment process are summarized. This review is an attempt to highlight recent and possibly forgotten findings of advances in chimeric antigen receptor T cell for treatment of hematological tumors. |
format | Online Article Text |
id | pubmed-10658259 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106582592023-11-07 CAR-T cell therapy for hematological malignancies: History, status and promise Wang, Chao Wang, Jianpeng Che, Shusheng Zhao, Hai Heliyon Review Article For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis. In recent years, immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-cell immunotherapy (CAR-T) uses the patient's own T cells to express chimeric antigen receptors. Chimeric antigen receptor (CAR) recognizes tumor-associated antigens and kills tumor cells. CAR-T has achieved good results in the treatment of hematological tumors. In 2017, the FDA approved the first CAR-T for the treatment of B-cell acute lymphoblastic leukemia (ALL). In October of the same year, the FDA approved CAR-T to treat B-cell lymphoma. In order to improve and enhance the therapeutic effect, CAR-T has become a research focus in recent years. The structure of CAR, the targets of CAR-T treatment, adverse reactions and improvement measures during the treatment process are summarized. This review is an attempt to highlight recent and possibly forgotten findings of advances in chimeric antigen receptor T cell for treatment of hematological tumors. Elsevier 2023-11-07 /pmc/articles/PMC10658259/ /pubmed/38027932 http://dx.doi.org/10.1016/j.heliyon.2023.e21776 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Wang, Chao Wang, Jianpeng Che, Shusheng Zhao, Hai CAR-T cell therapy for hematological malignancies: History, status and promise |
title | CAR-T cell therapy for hematological malignancies: History, status and promise |
title_full | CAR-T cell therapy for hematological malignancies: History, status and promise |
title_fullStr | CAR-T cell therapy for hematological malignancies: History, status and promise |
title_full_unstemmed | CAR-T cell therapy for hematological malignancies: History, status and promise |
title_short | CAR-T cell therapy for hematological malignancies: History, status and promise |
title_sort | car-t cell therapy for hematological malignancies: history, status and promise |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658259/ https://www.ncbi.nlm.nih.gov/pubmed/38027932 http://dx.doi.org/10.1016/j.heliyon.2023.e21776 |
work_keys_str_mv | AT wangchao cartcelltherapyforhematologicalmalignancieshistorystatusandpromise AT wangjianpeng cartcelltherapyforhematologicalmalignancieshistorystatusandpromise AT cheshusheng cartcelltherapyforhematologicalmalignancieshistorystatusandpromise AT zhaohai cartcelltherapyforhematologicalmalignancieshistorystatusandpromise |